Grupo Aeroportuario del Sureste, S. A. B. de C. V. (ASR)
NYSE: ASR · Real-Time Price · USD
304.03
+0.72 (0.24%)
Aug 1, 2025, 4:00 PM - Market closed
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Revance Therapeutics stock has a target of 310, which predicts a 1.96% increase from the current stock price of 304.03.
Price Target: $310.00 (+1.96%)
Analyst Consensus: Hold
* Price targets were last updated on Feb 12, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Revance Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold Maintains $321 → $310 | Hold | Maintains | $321 → $310 | +1.96% | Feb 12, 2025 |
| Barclays | Barclays | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 13, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Sell → Strong Buy Upgrades $274 → $326 | Strong Sell → Strong Buy | Upgrades | $274 → $326 | +7.23% | Jan 26, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $227 → $274 | Strong Sell | Maintains | $227 → $274 | -9.88% | Dec 18, 2023 |
| B of A Securities | B of A Securities | Sell → Strong Buy Upgrades n/a | Sell → Strong Buy | Upgrades | n/a | n/a | Dec 14, 2023 |
Financial Forecast
Revenue This Year
36.23B
from 31.33B
Increased by 15.63%
Revenue Next Year
40.00B
from 36.23B
Increased by 10.41%
EPS This Year
46.62
from 45.17
Increased by 3.22%
EPS Next Year
50.63
from 46.62
Increased by 8.60%
Financial currency is MXN. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 41.1B | 45.5B | 47.7B | |
| Avg | 36.2B | 40.0B | 42.8B | |
| Low | 30.5B | 33.8B | 36.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 31.2% | 25.5% | 19.3% | |
| Avg | 15.6% | 10.4% | 7.1% | |
| Low | -2.8% | -6.7% | -8.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 52.73 | 60.04 | 68.59 | |
| Avg | 46.62 | 50.63 | 56.17 | |
| Low | 41.12 | 43.81 | 47.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 16.7% | 28.8% | 35.5% | |
| Avg | 3.2% | 8.6% | 10.9% | |
| Low | -9.0% | -6.0% | -6.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.